HLB Therapeutics is committed to being a global biotechnology company.
We continue to grow and evolve into a company that helps chart a better future by expanding and developing a diversified business portfolio.
President and CEO
Ahn, Ki Hong
Date Founded
June 2000
Date Listed on the KOSDAQ
March 2010
Since 2014, HLB Therapeutics has signed contracts with major biotech companies and research institutes strategically selected in the United States for joint development of new drugs thus, laying a foundation for entering the biotechnology sector. We have established a corporation and are conducting global clinical business interactions.
· In January 2015, HLB Therapeutics established a joint venture, ReGenTree, LLC, for the global clinical development of a treatment (RGN-259) for ophthalmic diseases (e.g., dry eye, neurotrophic keratitis)
· In December 2015, Oblato, Inc., a wholly-owned US subsidiary of HLB Therapeutics was established for the global clinical development of a drug (OKN-007) to treat glioblastoma, a rare cancer.
· In December 2015, Oblato, Inc., a wholly-owned US subsidiary of HLB Therapeutics was established for the global clinical development of a drug (OKN-007) to treat glioblastoma, a rare cancer.
· In addition, we have been expanding the scope of our biotechnology by operating a vaccine business through YS Pharm which was merged in September 2018. Building on this, we are striving to become a global biotech company by advancing the development of innovative drugs. HLB Therapeutics is fast emerging as a company capable of sustainable management through the establishment of diversified business areas. We would like to ask you, our customers and shareholders, to support us on our journey into the future.
All employees of HLB Therapeutics Co., Ltd.
